Literature DB >> 11258559

Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma.

J A Green1, R Amaro, J S Barkin.   

Abstract

A population-based, case-control study to investigate the possible association between gastroesophageal reflux (GER) and adenocarcinoma of the esophagus and gastric cardia was performed. It demonstrated an odds ratio of 7.7 for esophageal adenocarcinoma in patients with GER symptoms. The frequency, severity, and duration of symptoms correlated with an increased risk of esophageal adenocarcinoma. A weaker association was noted for GER and adenocarcinoma of the gastric cardia. No association surfaced between GER and squamous cell carcinoma of the esophagus.

Entities:  

Mesh：

Year:  2000        PMID： 11258559     DOI： 10.1023/a:1005638924929

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


  12 in total

1.  Heartburn--a serious symptom.

Authors:  S Cohen; H P Parkman
Journal:  N Engl J Med       Date:  1999-03-18       Impact factor: 91.245

2.  Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy.

Authors:  D A Lieberman; M Oehlke; M Helfand
Journal:  Am J Gastroenterol       Date:  1997-08       Impact factor: 10.864

Review 3.  Barrett's esophagus.

Authors:  S J Spechler; R K Goyal
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

4.  Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma.

Authors:  J Lagergren; R Bergström; A Lindgren; O Nyrén
Journal:  N Engl J Med       Date:  1999-03-18       Impact factor: 91.245

5.  Prognosis of adenocarcinoma arising in Barrett's esophagus.

Authors:  S J Hoff; J L Sawyers; C D Blanke; H Choy; J R Stewart
Journal:  Ann Thorac Surg       Date:  1998-01       Impact factor: 4.330

6.  Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole.

Authors:  A Malesci; V Savarino; P Zentilin; M Belicchi; G S Mela; G Lapertosa; P Bocchia; G Ronchi; M Franceschi
Journal:  Gastrointest Endosc       Date:  1996-12       Impact factor: 9.427

7.  Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients.

Authors:  J H Peters; G W Clark; A P Ireland; P Chandrasoma; T C Smyrk; T R DeMeester
Journal:  J Thorac Cardiovasc Surg       Date:  1994-11       Impact factor: 5.209

8.  Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy.

Authors:  S Gore; C J Healey; R Sutton; I A Eyre-Brook; M W Gear; N A Shepherd; S P Wilkinson
Journal:  Aliment Pharmacol Ther       Date:  1993-12       Impact factor: 8.171

9.  Endoscopic surveillance of Barrett's esophagus. Does it help?

Authors:  J M Streitz; C W Andrews; F H Ellis
Journal:  J Thorac Cardiovasc Surg       Date:  1993-03       Impact factor: 5.209

10.  Barrett's esophagus. Functional assessment, proposed pathogenesis, and surgical therapy.

Authors:  C Iascone; T R DeMeester; A G Little; D B Skinner
Journal:  Arch Surg       Date:  1983-05
View more
  7 in total

1.  Influence of young age on outcome after esophagectomy for cancer.

Authors:  Anna M J van Nistelrooij; Elrozy R Andrinopoulou; Jan J B van Lanschot; Hugo W Tilanus; Bas P L Wijnhoven
Journal:  World J Surg       Date:  2012-11       Impact factor: 3.352

2.  Canadian consensus on medically acceptable wait times for digestive health care.

Authors:  William G Paterson; William T Depew; Pierre Paré; Denis Petrunia; Connie Switzer; Sander J Veldhuyzen van Zanten; Sandra Daniels
Journal:  Can J Gastroenterol       Date:  2006-06       Impact factor: 3.522

3.  Terrein performs antitumor functions on esophageal cancer cells by inhibiting cell proliferation and synergistic interaction with cisplatin.

Authors:  Yanqing Wu; Yinghua Zhu; Shunrong Li; Minhua Zeng; Junjun Chu; Pengnan Hu; Jingjing Li; Qiannan Guo; Xiao-Bin Lv; Guofu Huang
Journal:  Oncol Lett       Date:  2017-02-22       Impact factor: 2.967

4.  The efficacy of the application of the curative criteria of the 5rd edition Japanese gastric cancer treatment guidelines for early adenocarcinoma of the esophagogastric junction treated by endoscopic submucosal dissection.

Authors:  Zhihao Chen; Yong Liu; Lizhou Dou; Yueming Zhang; Shun He; Guiqi Wang
Journal:  Saudi J Gastroenterol       Date:  2021 Mar-Apr       Impact factor: 2.485

5.  Identification of DNA methylation-driven genes in esophageal squamous cell carcinoma: a study based on The Cancer Genome Atlas.

Authors:  Tong Lu; Di Chen; Yuanyong Wang; Xiao Sun; Shicheng Li; Shuncheng Miao; Yang Wo; Yanting Dong; Xiaoliang Leng; Wenxing Du; Wenjie Jiao
Journal:  Cancer Cell Int       Date:  2019-03-06       Impact factor: 5.722

6.  Trends in gastroesophageal reflux disease research: A bibliometric and visualized study.

Authors:  Tai Zhang; Beihua Zhang; Wende Tian; Yuchen Wei; Fengyun Wang; Xiaolan Yin; Xiuxiu Wei; Jiali Liu; Xudong Tang
Journal:  Front Med (Lausanne)       Date:  2022-09-29

7.  Symptoms and antireflux medication use following laparoscopic Nissen fundoplication: outcome at 1 and 4 years.

Authors:  Mark Bloomston; William Nields; Alexander S Rosemurgy
Journal:  JSLS       Date:  2003 Jul-Sep       Impact factor: 2.172
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.